PathAI
AI-powered pathology to improve patient outcomes and drug development
AI-Powered Summary
PathAI provides AI-powered digital pathology solutions for biopharma companies and anatomic pathology laboratories. Its AISight platform enables case management, image management, and deployment of AI algorithms for histopathology analysis, biomarker discovery, drug development, and clinical diagnostics. The platform has received FDA clearance for primary diagnosis and serves major biopharma companies and hospital systems worldwide.
Key Features
What makes PathAI stand out
Digital Image Management
AISight provides cloud-native case and image management for pathology slide workflows.
AI Algorithm Library
Offers a large menu of pre-built algorithms for biomarker scoring, tumor analysis, and tissue assessment.
Biomarker Quantification
Automated, reproducible scoring of biomarkers like PD-L1 and IHC breast panel markers.
Clinical Trial Support
GCP-compliant platform with trial-ready algorithms for standardized histopathology endpoints.
Workflow Optimization
Algorithms that prioritize tasks, reduce turnaround times, and balance pathologist workloads.
Annotation Tools
Built-in annotation capabilities with insights, powered by a network of 450+ pathologists.
FDA-Cleared Diagnosis
AISight Dx is FDA-cleared for primary diagnostic use in anatomic pathology.
Multi-Partner Ecosystem
Curated third-party algorithm integrations from partners like Mindpeak, Stratipath, and Primaa.
What's Great
- FDA-cleared platform (AISight Dx) for primary diagnosis, with FDA-qualified AI tools for clinical trials
- Largest menu of out-of-the-box pathology algorithms covering oncology, immunology, and inflammation
- Backed by 450+ board-certified pathologists and 32.5M+ annotations for rigorous AI training
- Adopted by 90% of the top 15 biopharma companies, demonstrating strong enterprise validation
- Cloud-native architecture supporting both clinical trial workflows and routine lab diagnostics
Things to Know
- Enterprise-only pricing with no self-service or transparent pricing tiers available
- Highly specialized for pathology — not applicable outside healthcare/life sciences use cases
- Some products remain designated 'Research Use Only' and are not cleared for diagnostic procedures
- Requires significant organizational infrastructure (scanners, LIS integration) to deploy effectively
Pricing Plans
All PathAI pricing tiers and features
Enterprise pricing requires contacting sales
Enterprise / Custom
Real Cost Breakdown
Hidden Costs
- Whole slide image scanner hardware may be required
- Integration with existing LIS/LIMS systems may require additional setup costs
- Individual AI algorithm modules may be priced separately from the base platform
Cost Saving Tips
- Contact PathAI directly for volume-based pricing based on caseload
- Consider starting with specific use cases (e.g., clinical trials only) before full lab deployment
PathAI is a premium enterprise platform with no public pricing; costs are likely substantial and tailored to institutional-scale pathology operations.
Price Comparison
Compare PathAI with similar tools
PathAI offers enterprise pricing. Contact their sales team for a custom quote based on your needs.
Best For
Biopharma companies and pathology labs needing AI-driven tissue analysis
Who Should NOT Use This
- Individual researchers or small academic labs with limited budgets — PathAI is an enterprise platform with custom pricing designed for large biopharma companies and institutional pathology labs, making it inaccessible for small-scale users.
- Healthcare organizations outside of pathology (e.g., radiology, cardiology) — PathAI is exclusively focused on histopathology and tissue analysis; it has no tools for other medical imaging or clinical specialties.
- Labs seeking fully autonomous AI diagnosis without pathologist oversight — Many PathAI products are designated Research Use Only, and even FDA-cleared tools are designed to assist pathologists rather than replace them entirely.
- Organizations requiring on-premise-only deployment — AISight is a cloud-native platform, which may not meet the requirements of organizations with strict on-premise data residency policies.
Competitive Position
PathAI uniquely combines FDA-cleared diagnostic capabilities, the largest proprietary pathology AI algorithm menu, and a 450+ pathologist contributor network, making it the most comprehensive integrated AI pathology platform for both clinical and biopharma use.
When to Choose PathAI
- When running biopharma clinical trials that require standardized AI-assisted histopathology endpoints
- When deploying enterprise-scale digital pathology across a large laboratory network
- When needing FDA-cleared AI pathology tools for primary diagnosis in anatomic pathology
- When seeking a comprehensive platform that combines image management, case management, and AI algorithms
When to Look Elsewhere
- When needing radiology or non-pathology medical imaging AI solutions
- When operating a small lab with limited budget and no enterprise procurement capability
- When requiring open-source or self-hosted pathology AI tools for academic research
- When needing only basic slide scanning and viewing without AI capabilities
Strongest alternative: Proscia (Concentriq)
Learning Curve
Prerequisites
Common Challenges
- Integrating AISight with existing laboratory information systems
- Training pathology staff to adopt digital workflows over traditional microscope-based methods
- Understanding which AI algorithms are appropriate for specific clinical or research use cases
- Navigating regulatory designations (FDA-cleared vs. Research Use Only) for different products
Frequently Asked Questions
Common questions about PathAI
Compare PathAI
See how PathAI stacks up against alternatives
Ready to try PathAI?
Join thousands of users who are already using PathAI to supercharge their workflow.
Get Started Free